Ph.D., Professor, Principal Investigator
Laboratory of Applied Genetics
Research Interests or Current Research Focus
1. Utilizing in vitro tumor models to study molecular networks underlying tumorigenesis and development.
2. Utilizing in vitro tumor models of targeted therapy to study molecular networks underlying cell differentiation and apoptosis.
3. Utilizing clinical tumor samples to classify tumor types and identify specific molecular signatures.
4. Identification of stem cell specific marker molecules.
5. Study of specific HLA associated diseases using HLA genechip.
Major Research Achievement
During the past eight years, Dr. Ji Zhang and his coworkers have pioneered the applications of molecular networks in cancer related translational research. Through systems approaches incorporated with the high-throughput technologies of transcriptome profiling and ChIP-on-chip/seq, computational biology (CPP-SOM, SOM-SVD and SOM-NMF) and conventional assays, they have performed systems analyses of several pathogenic and therapeutic models in a quantitative manner, obtaining the novel insights into the transcriptional regulatory network underlining tumorigenesis and its corresponding effective therapies at both spatial and temporal levels. These academic achievements have been peer-reviewed and repeatedly published in the journals such as Cancer cell, Dev. Cell, Blood, PNAS, Cancer Research, JBC, Plos One, Current Drug Metabolism etc.. Also, a number of patents and software copyrights have been granted. Research in Dr. Zhang’s groups have been supported by Science and Technology Dept. of China (973, 863 major grants), Nature Science Foundation of China (Major grants), Chinese Academy Innovation grants and European Community (Frame 7 project grant).
1991 Ph. D., Medical Science from University Leuven, Belgium
1982 B.S., Xinjiang University, China
1991-1993 Postdoctoral Fellow, University of Michigan
Major Academic Appointments
1993-1998 Senior Staff Fellow, NIH
1999-2003 Assistant Professor, Nebraska Medical Center
2002-present the vice director of State Key Laboratory of Medical Genomics and the principal investigator of
Sino-French Laboratory of Genomics and Life Sciences, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine
2002-present Principal Investigator of Applied Genomics Lab, Institute of Health Sciences,
Shanghai Institutes for Biological Sciences, CAS / Shanghai Jiao Tong University of medicine, China
Honors, Certificates, and Academic Society
1988 Scientific Research Foundation Fellowship. Brussel, Belgium
1995 Excellent Merits. Second Annual Scientific Retreat of National Center for Human Genome Research, NIH
1996 Excellent Merits. Third Annual Scientific Retreat of National Center for HumanGenome Research, NIH
1998 Excellent Merits. Fifth Annual Scientific Retreat of National Human Genome Research Institute, NIH
1999 Research Fellow VP. National Human Genome Research Institute, NIH
2003 Young Scientist in Excellency, China Nature Science Fundation
2003 100-Talent Plan, Chinese Academy of Science
2005 The Second Prize of Shanghai Medical Science and Technology Award
2006 The Second Prize of Chinese Medical Science and Technology Award
2007 The First Prize from Science and Technology Commission of Shanghai Municipality Progress Award
2007 The First Prize from Ministry of Education Progress Award for Science and Technology
- Qian M, Jin W, Zhu X, Jia X, Yang X, Du Y, Wang K, Zhang J. Structurally differentiated cis-elements that interact with PU.1 are functionally distinguishable in acute promyelocytic leukemia. J Hematol Oncol. 2013; 6: 25. Published online 2013 April 2. doi: 10.1186/1756-8722-6-25.
- Jin W, Wu K, Li YZ, Yang WT, Zou B, Zhang F, Zhang J, Wang KK. AML1-ETO targets and suppresses cathepsin G, a serine protease, which is able to degrade AML1-ETO in t(8;21) acute myeloid leukemia. Oncogene. 2013 Apr 11;32(15):1978-87. doi: 10.1038/onc.2012.204.
- Zhu X, Zhang H, Qian M, Zhao X, Yang W, Wang P, Zhang J, Wang K. The significance of low PU.1 expression in patients with acute promyelocyticleukemia. J Hematol Oncol. 2012 May 8; 5: 22.
- Zou D, Yang X, Tan Y, Wang P, Zhu X, Yang W, Jia X, Zhang J, Wang K. Regulation of the hematopoietic cell kinase (HCK) by PML/RARα and PU.1 in acute promyelocytic leukemia. Leukemia Res. 2012 Feb; 36(2):219-223.
- Wu K, Dong D, Fang H, Levillain F, Jin W, Mei J, Gicquel B, Du Y, Wang K, Gao Q, Neyrolles O, Zhang J. An interferon-related signature in the transcriptional core response of human macrophages to mycobacterium tuberculosis infection. PLoS One. 2012;7(6):e38367.
- Zhang Y, Du Y, Le W, Wang K, Kieffer N, Zhang J. Redox Control of the Survival of Healthy and Diseased cells. Antioxid Redox Signal. 2011 Dec 1;15(11):2867-908.
- Zhang Y, Wang C, Wang H, Wang K, Du Y, Zhang J. Combination of Tetrandrine with cisplatin enhances cytotoxicity through growth suppression and apoptosis in ovarian cancer in vitro and in vivo. Cancer Lett. 2011;(304): 21-32.
- Shi J, Yang W, Chen M, Du Y, Zhang J, Wang K. AMD, an Automated Motif Discovery Tool Using Stepwise Refinement of Gapped Consensuses. PLoS One. 2011;6(9):e24576.
- Fang H, Du Y, Xia L, Li J, Zhang J, Wang K. A Topology-Preserving Selection and Clustering Approach to Multi-Dimensional Biological Data. OMICS JIB. 2011 Jul-Aug;15(7-8):483-94.
- Fang H, Jin W, Yang Y, Jin Y, Zhang J, Wang K. An organogenesis network-based comparative transcriptome analysis for understanding early human development in vivo and in vitro. BMC Syst Biol. 2011 Jul 6;5:108.
- Jiang L, Pan X, Chen Y, Wang K, Du Y, Zhang J. Preferential involvement of both ROS and ceramide in fenretinide-induced apoptosis of HL60 rather than NB4 and U937 cells. Biochem Biophys Res Commun. 2011 Feb 11;405(2):314-8.
- Fang H, Yang Y, Li C, Fu S, Yang Z, Jin G, Wang K, Zhang J, Jin Y. Transcriptome Analysis of Early Organogenesis in Human Embryos. Dev Cell. 2010 Jul 20;19(1):174-184.
- Shi JT, Yang WT, Chen MJ, Du YZ, Wang KK, and Zhang J. AMD, an automated motif discovery tool by stepwise refinement of gapped consensuses. Genome Biology. in revision (Corresponding author)
- Wang KK, Shi JT, Wang P, Zhu XH, He MM, Fang H, Du YZ and Zhang J. PML/RARa Targets Promoter Regions Containing PU.1 Consensus and RARE Half Sites in Acute Promyelocytic Leukemia. Cancer Cell. 17, 186–197, February 17, 2010(Corresponding author)
- Wang K, Fang H, Xiao D, Zhu X, He M, Pan X, Shi J, Zhang H, Jia X, Du Y and Zhang J. Converting Redox Signaling to Apoptotic Activities by Stress-Responsive Regulators HSF1 and NRF2 in Fenretinide Treated Cancer Cells. PLoS One. 2009, 4, e7538 (Corresponding author)
- Fang H, Wang KK and Zhang J. Transcriptome and proteome analysis of drug interaction with natural products. Current Drug Metabolism. 2008,9:1038-1048(Corresponding author)
- Fu SJ, Zhao HG, Abzhanov A, Crawford K, Zhou O-M L, Du YZ, Kuo WP, Zhang J, Jiang M and Jin G. Peripheral arterial occlusive disease: global gene expression analyses suggest a major role for immune and inflammatory responses. BMC Genomics. 2008,1:9:369(Corresponding author)
- Rodius S, Moes M, Chaloin O, Schffner-Reckinger E, Lippens G, Zhang J and Kieffer N. The talin rod IBS2 α -helix interacts with the β3 integrin cytoplasmic tail membrane proximal helix by establishing charge complementary salt bridges. JBC. 2008 Aug 29;283(35):24212-23.
- Zhou GB, Zhang J, Chen SJ and Chen Z. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy. Phil. Trans. R. Soc. B. 2007, 362:959-971.
- Xuetao Bai, Baiwei Gu, Tong Yin, Chao Niu, Xiaodong Xi, Ji Zhang, Zhu Chen and Saijuan Chen. Trans-Repressive Effect of NUP98-PMX1 on PMX1-Regulated c-FOS Gene through Recruitment of Histone Deacetylase 1 by FG Repeats. Cancer Res. 2006 May 1;66(9):4584-90.
- Yanzhi Du, Kankan Wang, Hai Fang, Junmin Li, Dakai Xiao, Peizheng Zheng, Yulong Chen, Huiyong Fan, Xiaoling Pan, Chunjun Zhao, Qinghua Zhang, Imbeaud Sandrine, Graudens Esther, Eveno Eric, Auffray Charles, Saijuan Chen, Zhu Chen, Ji Zhang. Coordination of intrinsic, extrinsic, and endoplasmic reticulum-mediated apoptosis by imatinib mesylate combined with arsenic trioxide in chronic myeloid leukemia. Blood. 2006 Feb 15;107(4):1582-90. (Corresponding author)
- Ke Xu, Fabien Guidez, Annegret Glasow, Danna Chung, Kevin Petrie, Kimberly Stegmaier, Kan-Kan Wang, Ji Zhang, Yongkui Jing, Arthur Zelent, and Samuel Waxman. Benzodithiophenes Potentiate Differentiation of Acute Promyelocytic Leukemia Cells by Lowering the Threshold for Ligand-Mediated Corepressor/Coactivator Exchange with Retinoic Acid Receptor and Enhancing Changes in all-trans-Retinoic Acid–Regulated Gene Expression. Cancer Res. 2005 Sep1; 65(17):7856-65.
- Peizheng Zheng, Kankan Wang, Qunye Zhang, Qiuhua Huang, Yanzhi Du, Qinghua Zhang, Dakai Xiao, Shuhong Shen, Sandrine Imbeaud, Eric Eveno, Chunjun Zhao, Yulong Chen, Huiyong Fan, Samuel Waxman, Charles Auffray, Gang Jin, Saijuan Chen, Zhu Chen, Ji Zhang. Systems analysis of transcriptome and proteome in retinoic acid arsenic trioxide-induced cell differentiation apoptosis of promyelocytic leukemia. Proc Natl Acad Sci U S A. 2005 May 24; 102(21):7653-7658. (Corresponding author)